» Articles » PMID: 21383100

Fluoroquinolone and Quinazolinedione Activities Against Wild-type and Gyrase Mutant Strains of Mycobacterium Smegmatis

Overview
Specialty Pharmacology
Date 2011 Mar 9
PMID 21383100
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Quinazolinediones (diones) are fluoroquinolone-like inhibitors of bacterial gyrase and DNA topoisomerase IV. To assess activity against mycobacteria, C-8-methoxy dione derivatives were compared with cognate fluoroquinolones by using cultured Mycobacterium smegmatis. Diones exhibited higher MIC values than fluoroquinolones; however, MICs for fluoroquinolone-resistant gyrA mutants, normalized to the MIC for wild-type cells, were lower. Addition of a 3-amino group to the 2,4-dione core increased relative activity against mutants, while alteration of the 8-methoxy group to a methyl or of the 2,4-dione core to a 1,3-dione core lowered activity against mutants. A GyrA G89C bacterial variant was strikingly susceptible to most of the diones tested; in contrast, low susceptibility to fluoroquinolones was observed. Many of the bacteriostatic differences between diones and fluoroquinolones were explained by interactions at the N terminus of GyrA helix IV revealed by recently published X-ray structures of drug-topoisomerase-DNA complexes. When lethal activity was normalized to the MIC in order to minimize the effects of drug uptake, efflux, and ternary complex formation, a 3-amino-2,4-dione exhibited killing activity comparable to that of a cognate fluoroquinolone. Surprisingly, the lethal activity of the dione was inhibited less by chloramphenicol than that of the cognate fluoroquinolone. This observation adds the 2,4-dione structural motif to the list of structural features known to impart lethality to fluoroquinolone-like compounds in the absence of protein synthesis, a phenomenon that is not explained by X-ray structures of drug-enzyme-DNA complexes.

Citing Articles

Target-Mediated Fluoroquinolone Resistance in : Actions of Ciprofloxacin against Gyrase and Topoisomerase IV.

Collins J, Oviatt A, Chan P, Osheroff N ACS Infect Dis. 2024; 10(4):1351-1360.

PMID: 38606464 PMC: 11015056. DOI: 10.1021/acsinfecdis.4c00041.


Synthesis of 3-(Pyridin-2-yl)quinazolin-2,4(13)-diones via Annulation of Anthranilic Esters with -pyridyl Ureas.

Baykova S, Geyl K, Baykov S, Boyarskiy V Int J Mol Sci. 2023; 24(8).

PMID: 37108796 PMC: 10142796. DOI: 10.3390/ijms24087633.


Role of the Water-Metal Ion Bridge in Quinolone Interactions with Gyrase.

Carter H, Wildman B, Schwanz H, Kerns R, Aldred K Int J Mol Sci. 2023; 24(3).

PMID: 36769202 PMC: 9917921. DOI: 10.3390/ijms24032879.


Discovery of Quinazoline-2,4(1,3)-Dione Derivatives as Potential Antibacterial Agent: Design, Synthesis, and Their Antibacterial Activity.

Boshta N, El-Essawy F, Alshammari M, Noreldein S, Darwesh O Molecules. 2022; 27(12).

PMID: 35744976 PMC: 9228007. DOI: 10.3390/molecules27123853.


A Preclinical Candidate Targeting Mycobacterium tuberculosis KasA.

Inoyama D, Awasthi D, Capodagli G, Tsotetsi K, Sukheja P, Zimmerman M Cell Chem Biol. 2020; 27(5):560-570.e10.

PMID: 32197094 PMC: 7245553. DOI: 10.1016/j.chembiol.2020.02.007.


References
1.
Bax B, Chan P, Eggleston D, Fosberry A, Gentry D, Gorrec F . Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature. 2010; 466(7309):935-40. DOI: 10.1038/nature09197. View

2.
Critchlow S, Maxwell A . DNA cleavage is not required for the binding of quinolone drugs to the DNA gyrase-DNA complex. Biochemistry. 1996; 35(23):7387-93. DOI: 10.1021/bi9603175. View

3.
Liu Q, Wang J . Identification of active site residues in the "GyrA" half of yeast DNA topoisomerase II. J Biol Chem. 1998; 273(32):20252-60. DOI: 10.1074/jbc.273.32.20252. View

4.
Chen C, Malik M, Snyder M, Drlica K . DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J Mol Biol. 1996; 258(4):627-37. DOI: 10.1006/jmbi.1996.0274. View

5.
Wohlkonig A, Chan P, Fosberry A, Homes P, Huang J, Kranz M . Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010; 17(9):1152-3. DOI: 10.1038/nsmb.1892. View